Skip to main content
Armeen Mahvash, MD, Radiology, Houston, TX, University of Texas M.D. Anderson Cancer Center

ArmeenMahvashMD

Radiology Houston, TX

Interventional Neuroradiology, Vascular & Interventional Radiology

Physician

Dr. Mahvash is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Mahvash's full profile

Already have an account?

Summary

  • Dr. Armeen Mahvash is a radiologist in Houston, TX and is affiliated with University of Texas M.D. Anderson Cancer Center. He received his medical degree from Baylor College of Medicine and has been in practice 18 years. He specializes in vascular & interventional radiology.

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Vascular and Interventional Radiology, 2005 - 2006
  • University of Texas Health Science Center at Houston
    University of Texas Health Science Center at HoustonResidency, Radiology-Diagnostic, 2000 - 2004
  • John Peter Smith Hospital (Tarrant County Hospital District)
    John Peter Smith Hospital (Tarrant County Hospital District)Internship, Transitional Year, 1999 - 2000
  • Baylor College of Medicine
    Baylor College of MedicineClass of 1999

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2004 - 2024
  • American Board of Radiology Interventional Radiology and Diagnostic Radiology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Sirtex Commences DOORwaY-90 Study for SIR-Spheres Therapy as First-Line Treatment of Unresectable HCC
    Sirtex Commences DOORwaY-90 Study for SIR-Spheres Therapy as First-Line Treatment of Unresectable HCCMay 10th, 2021
  • Sirtex Medical Announces New SIR-Spheres(R) DOORwaY-90 Study: The First Prospective Multicenter U.S.-based Trial for Registration as First-Line Treatment for Hepatocellular Carcinoma
    Sirtex Medical Announces New SIR-Spheres(R) DOORwaY-90 Study: The First Prospective Multicenter U.S.-based Trial for Registration as First-Line Treatment for Hepatocellular CarcinomaMarch 22nd, 2021

Professional Memberships

Hospital Affiliations